In 2020, there was some controversy over whether it was safe to take ibuprofen for COVID-19 symptoms. Now that some time has passed, learn what researchers say about the safety of nonsteroidal anti-inflammatory drugs (NSAIDs) for treating COVID-19.
References
Bastolla, U., et al. (2022). Is Covid-19 severity associated with ACE2 degradation? Frontiers in Drug Discovery.
BMJ. (2020). Covid-19: Ibuprofen should not be used for managing symptoms, say doctors and scientists. The BMJ.
Centers for Disease Control and Prevention. (n.d.). COVID-19.
Edmunds, D. R., et al. (2020). World Health Organization backs call to avoid ibuprofen for coronavirus. The Jerusalem Post.
European Medicines Agency. (2020). EMA gives advice on the use of non-steroidal anti-inflammatories for Covid-19.
McKenna, M. (2020). The ibuprofen debate reveals the danger of Covid-19 rumors. Wired.
Perico, N., et al. (2023). Home as the new frontier for the treatment of COVID-19: The case for anti-inflammatory agents. The Lancet Infectious Diseases.
University of Basel. (2020). Ibuprofen and COVID-19.
Willsher, K. (2020). Anti-inflammatories may aggravate Covid-19, France advises. The Guardian.
Wong, A. Y. S., et al. (2021). Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals of Rheumatic Diseases.
World Health Organization. (2020). The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19.
Yang, X., et al. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet Respiratory Medicine.
Zhao, H., et al. (2022). Prevalence of NSAID use among people with COVID-19 and the association with COVID-19 related outcomes: Systematic review and meta-analysis. British Journal of Clinical Pharmacology.
Why trust our experts?
Search and compare options
